Abstracts tagged "immunoglobulin (IG) and rheumatoid arthritis (RA)"

Abstract Number: 8 • 2018 ACR/ARHP Annual Meeting
Repertoire Studies in Rheumatoid Arthritis Reveal B-Cell Distortions and Baseline Shifts in Unmutated IgG
Yan Wang¹, Katy A. Lloyd², Sunithi Gunasekera³, Camilla Eriksson³, Daniel Ramsköld², Karin Lundberg⁴, Per-Johan Jakobsson¹, Ulf Göransson³, Vivianne Malmström¹ and Caroline Grönwall⁵, ¹Rheumatology Unit, Dept. of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ³Division of Pharmacognosy, Dept. of Medicinal Chemistry, Uppsala University, Uppsala, Sweden, ⁴Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ⁵Dep. of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: The immunological hallmark of rheumatoid arthritis (RA) is autoreactivity to citrullinated proteins and rheumatoid factor activity. Hence, the adaptive immune system and B cells…
Abstract Number: 19 • 2018 ACR/ARHP Annual Meeting
Citrulline-Multispecific B Cell Receptor Clades in Rheumatoid Arthritis
Philip J. Titcombe^1,2, Natalie Sippl³, Monika Hansson⁴, Lena Israelsson³, Khaled Amara³, Timothy B. Niewold⁵, Lars Klareskog², Vivianne Malmström² and Daniel L. Mueller⁶, ¹The Center for Immunology, Dept. of Medicine, University of Minnesota Medical School, Minneapolis, MN, ²Rheumatology Unit, Dept. of Medicine, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁵Colton Center for Autoimmunity, New York University, New York, NY, ⁶Medicine/Rheumatic and Autoimmune Diseases, University of Minnesota Medical School, Minneapolis, MN
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) have proven highly useful as biomarkers in rheumatoid arthritis (RA) and appear to be important to disease pathogenesis. Nevertheless, the…
Abstract Number: 1484 • 2018 ACR/ARHP Annual Meeting
Value of Anti-RA33 Isotypes in an European Rheumatoid Arthritis Patient Cohort
Maresa Grundhuber¹, Daniela Sieghart², Günter Steiner², Maryam Poorafshar³ and Sascha Swiniarski¹, ¹Thermo Fisher Scientific, Freiburg, Germany, Freiburg, Germany, ²Division of Rheumatology, Department of Internal Medicine III, Medical University Vienna, Austria, Vienna, Austria, ³Thermo Fisher Scientific, Uppsala, Sweden, Uppsala, Sweden
Background/Purpose: Early diagnosis of rheumatoid arthritis (RA) leading to effective treatment is essential to improve prognosis and to prevent disease progression. Anti-cyclic citrullinated peptide (CCP)…
Abstract Number: 477 • 2017 ACR/ARHP Annual Meeting
Monoclonal ACPA-IgG Feature Extensive Fab Glycosylation
Katy A. Lloyd¹, Johanna Steen¹, Philip J. Titcombe^2,3, Khaled Amara⁴, Diana Zhou¹, Lena Israelsson⁵, Susanna L. Lundström⁶, Daniel L. Mueller³, Lars Klareskog¹, Vivianne Malmström¹ and Caroline Grönwall⁷, ¹Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ²Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Sweden, Sweden, ³Dept. of Medicine, University of Minnesota Medical School, Minneapolis, MN, ⁴Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ⁵Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ⁶Dept. of Medical Biochemistry and Biophysics, Division of Physiological Chemistry, Karolinska Institutet, Stockholm, Sweden, ⁷Dep. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Fab-glycosylation is found in ~15-25% serum IgG and while its exact consequence remains unknown, it may alter IgG functionality. Recent data revealed elevated Fab-glycosylation…
Abstract Number: 834 • 2017 ACR/ARHP Annual Meeting
Citrulline-Polyspecific B Cell Antigen Receptors Arising from Somatic Hypermutation within Clades Demonstrate Pathogenicity in Rheumatoid Arthritis
Philip J. Titcombe^1,2, Gustaf Wigerblad³, Natalie Sippl³, Na Zhang¹, Anna K. Shmagel⁴, Peter Sahlström⁵, Yue Jack Zhang¹, Laura Barsness Motschenbacher¹, Yogita Ghodke-Puranik⁶, Monika Hansson⁷, Lena Israelsson⁵, Timothy B. Niewold⁸, Lars Klareskog⁹, Camilla Svensson¹⁰, Khaled Amara⁷, Vivianne Malmström¹¹ and Daniel L. Mueller¹, ¹Medicine/Rheumatic and Autoimmune Diseases, University of Minnesota Medical School, Minneapolis, MN, ²Rheumatology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ³Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Rheumatic & Autoimmune Diseases, University of Minnesota Medical School, Minneapolis, MN, ⁵Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ⁶Colton Center for Autoimmunity, New York University, New York, NY, ⁷Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ⁸Rheumatology and Immunology, Mayo Clinic, Rochester, MN, ⁹Rheumatology unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ¹⁰Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden, ¹¹Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Citrulline–modified proteins arising from the post-translational modification of arginine residues are recognized as primary rheumatoid arthritis (RA) autoantigen targets based on the strong association…
Abstract Number: 643 • 2016 ACR/ARHP Annual Meeting
Exposure-Response Analyses of Efficacy of ABT-122, a Dual-Variable Domain Immunoglobulin (DVD-Ig™) Targeting TNF-α and IL-17A, Compared with Adalimumab in Subjects with Rheumatoid Arthritis and Background MTX
Amit Khatri¹, Ben Klunder², Mukul Minocha³, Heikki T. Mansikka¹ and Ahmed A. Othman¹, ¹AbbVie Inc., North Chicago, IL, ²AbbVie, Ludwigshafen am Rhein, Germany, ³Clinical Pharmacology and Pharmacometrics, AbbVie, North Chicago, IL
Background/Purpose: ABT-122 is a novel dual-variable domain immunoglobulin (DVD-IgTM), which specifically neutralizes both TNF alpha (TNFα) and interleukin-17A (IL-17). Both cytokines are expressed at increased…
Abstract Number: 868 • 2013 ACR/ARHP Annual Meeting
Serum Immunoglobulin Free Light Chains and Rheumatoid Arthritis: A Population-Based Study
John M. Davis III¹, S. Vincent Rajkumar², Cynthia S. Crowson³, Xiaoli Deng⁴, Angela Dispenzieri², Dirk R. Larson⁵, Terry M. Therneau³, Eric L. Matteson¹, Robert A. Kyle², Jerry Katzmann⁶ and Sherine E. Gabriel⁷, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Hematology, Mayo Clinic, Rochester, MN, ³Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Rheumatology and Immunology, Peking University Third Hospital, Beijing, China, ⁵Health Sciences Research, Mayo Clinic, Rochester, MN, ⁶Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, ⁷Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Serum immunoglobulin free light chains (FLCs) represent biomarkers of B-cell activation and have been associated with rheumatoid arthritis (RA) as well as all-cause mortality…
Abstract Number: 1212 • 2012 ACR/ARHP Annual Meeting
Elevated Fecal Secretory Immunoglobulin A, Anti-Cyclic Citrullinated Peptide Antibodies, and Cytokine Levels in Rheumatoid Arthritis Patients
Sam Dalvi¹, Jose U. Scher*¹, Mukundan Attur², Jyoti Patel³ and Steven B. Abramson⁴, ¹Rheumatology, NYU Hospital for Joint Diseases, New York, NY, ²Division of Rheumatology, Department of Medicine, NYU Hospital for Joint Diseases, New York, NY, ³Rheumatology, NYU Langone Medical Center, New York, NY, ⁴Dept of Rheumatology/Medicine, NYU Langone Medical Center, New York, NY
Background/Purpose: Rheumatoid arthritis (RA) is a complex autoimmune disease with genetic and environmental contributions. There has been increasing interest in the microbiome and its potential…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].